The aim is to develop an integrated technology for organic waste treatment resulting in significantly lower carbon footprint approximately 1-2 kg eq. of CO2 for proteinous feed production by biological methanation, nutrient recovery and single cell protein (SCP) production for animal feed. This will be achieved by addressing three objectives: 1) Technical: Electrochemical N and P recovery from digestate, and systems analysis of the proposed technology for the process. 2) Social: By accepting to collaborate in the development and acceptance of PROFIT the agricultural sector becomes part of the community. In this respect, PROFIT contributes to the social dimension of sustainability, since it provides new opportunities to the agricultural sector, namely its involvement in the co-creation of a product that benefits the economy and the environment. 3) Economic: the sustainability and economic feasibility of PROFIT will be evaluated using life cycle, techno-economic assessment and market penetration actions at each level of development.

Cervical cancer is the fourth most prevalent cancer in women with more than 600,000 women being diagnosed globally every year and 341,000 dying. In Scandinavia alone 1,453 women were diagnosed and 441 died in 2020. Late-stage cervical cancer patients have few and ineffective treatment options and there is thus a high unmet medical need for more effective treatment options. Tumor Infiltrating Lymphocyte (TIL) therapy is the most promising cell-based therapy against solid tumors and holds great promise also in cervical cancer where deep and long-lasting clinical responses and curative potential have been demonstrated. In the pro-novoleucel project we expect to further improve the clinical response of TIL therapy and build upon some of the most recent advances in immune oncology: By combining Cbio’s CPI-enhanced TIL product that generates a much broader T-cell repertoire with the pro-lymphocyte technology from Karolinska Institute that is arming the TILs against the hostile tumor microenvironment, we are simultaneously addressing two of the major escape mechanisms for cancer to evade the immune system. With a clinical proof-of-concept in cervical cancer, we plan to take pro-novoleucel through clinical development to make it a globally available product. Beyond this, pro-novoleucel can be extended into other solid cancer indications ultimately helping a large fraction of the 16 million people who die from solid cancers each year.

PURfection will pursue total recyclability of the high-performance and difficult to replace plastic material polyurethane (PUR). Its excellent performance and extensive range of applications have resulted in 24 m tones of PUR being produced each year, a number that is predicted to grow by 7% the coming years. Today’s PUR recycling methods have reached their final development stage rendering 70% of all future PUR waste destined for landfilling or incineration. PURfections predecessor, RePURpose, successfully identified both key infliction points in the existing PUR value chain and developed novel recycling technology. PURfection will convert these findings to innovation by implementing closed-loop recycling for PUR production spill and deliver proof-of-concept for full recycling of EoL PUR waste streams. All developed solutions will be evaluated using techno-economic analysis and life-cycle-assessment tools and become part of proving new value chains and business models for PUR recycling. PURfection holds the potential to eliminate 7% of the total Danish CO2-eq emissions from incineration of plastic waste, while simultaneously aiding the consortium partners to expand their market shares of 5%, corresponding to double-digit m EUR in value capture. With an onset at kilogram scale, PURfection will collect, chemically deconstruct, and separate PUR waste streams into valuable chemical building blocks, that will reenter the production of new PUR products.